{
  "docId": "019de075-d132-769f-97bd-4a840dd24899",
  "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 56,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a bar chart to illustrate the additive effect of combining two therapies, with a supporting table for N, maintenance remission, and safety.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/40",
  "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899",
  "deckJsonHref": "/decks/019de075-d132-769f-97bd-4a840dd24899.json",
  "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.335,
        "x": 0.645,
        "y": 0.325
      },
      "kind": "callout",
      "text": "Despite non-optimal components, JNJ combination (JNJ-78934804) delivered superior UC efficacy compared to any single agent. Spyre aims to build on this success with combinations of best-in-class mAbs from superior MOAs.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "122bf700-025e-4067-b402-c0f2342c5c8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.12,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Clinical remission rates (induction) for Golimumab, Guselkumab, and Combination",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37cd5cc3-78c8-46bd-b920-a3464a151248",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "NOTE: *In VEGA, only guselkumab (IL-23) was continued in maintenance for the combo arm in a treat-through design; Spyre plans to use combinations in maintenance.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75eab2c5-f334-4226-aa6f-10aa5e0110a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.55,
        "x": 0.02,
        "y": 0.63
      },
      "kind": "table",
      "text": "Table showing N, Maintenance remission, and Safety for the three groups",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8deaaac7-7b10-4253-87a9-84d8100d98a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "JNJ's VEGA study demonstrated power of combination therapy despite relative weakness of components",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbc75fd8-fd0b-401f-b41b-9f333773631f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "5f6d4669-5ccc-4861-a108-d4868f8f0645",
      "evidence": "Comparing single agents vs combination therapy efficacy",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 44,
      "from": 10,
      "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}